[THE DRUGS (PRICES CONTROL) ORDER, 1995][1] In exercise of the
powers conferred by Section 3 of the Essential Commodities Act, 1955 (10 of
1955), the Central Government hereby makes the following Order, namely: (1)
This
Order may be called the Drugs (Prices Control) Order, 1995. (2)
It
shall come into force on the date of its publication in the official Gazette. In this Order, unless the context otherwise
requires, (a)
"bulk
drug" means any pharmaceutical, chemical, biological or plant product
including its salts, esters, stereo-isomers and derivatives, conforming to
pharmacopoeial or other standards accepted under the Drugs and Cosmetics Act,
1940 (23 of 1940), which is used as such, or as an ingredient in any
formulation; (b)
"capital
employed" means net fixed assets plus working capital of a manufacturer in
relation to manufacture of bulk drugs; (c)
"ceiling
price" means a price fixed by the Government for Scheduled formulations in
accordance with the provisions of paragraph 9; (d)
"dealer"
means a person carrying on the business of purchase or sale of drugs, whether
as a wholesaler or retailer and whether or not in conjunction with any other
business, and includes his agent; (e)
"distributor"
means distributor of drugs or his agent or a stockist appointed by a
manufacturer or an importer for stocking his drugs for resale to a dealer; (f)
"drug"
includes- (i)
all
medicines for internal or external use of human beings or animals and all
substances intended to be used for, or in, the diagnosis, treatment, mitigation
or prevention of any disease or disorder in human beings or animals, including
preparations applied on human body for the purpose of repelling insects like
mosquitoes; (ii)
such
substances, intended to affect the structure or any function of the human or
animal body or intended to be used for the destruction of vermin or insects
which cause disease in human beings or animals, as may be specified from time
to time by the Government by notification in the official Gazette; and (iii)
bulk
drugs and formulations; (g)
"Form"
means a Form specified in the Second Schedule; (h)
"formulation"
means a medicine processed out of, or containing one or more bulk drug or drugs
with or without the use of any pharmaceutical aids, for internal or external
use for or in the diagnosis, treatment, mitigation or prevention of disease in
human beings or animals, but shall not include, (i)
any
medicine included in any bona fide Ayurvedic (including Sidha) or Unani (Tibb)
systems of medicines; (ii)
any
medicine included in the Homeopathic system of medicine; and (iii)
any
substance to which the provisions of the Drugs and Cosmetics Act, 1940 (23 of
1940) do not apply; (i)
"free
reserve" means a reserve created by appropriation of profits, but does not
include reserves provided for contingent liability, disputed claims, goodwill,
revaluation and other similar reserves; (j)
"Government"
means the Central Government; (k)
"import"
with its grammatical variations and cognate expressions means bringing into
India from a place outside India, and "importer", in relation to any
goods at any time between their importation and consumption, includes any owner
or any person holding himself out to be the importer; [2][(kk) "local
taxes" means any tax or levy (except excise duty included in retail price)
paid and/or payable to the Central Government or State Government or any Local
authority under any law by the manufacturer or his agent or dealer;] (l)
"manufacture",
in relation to any drug, includes any process or part of a process for making,
altering, finishing, packing, labelling, breaking or otherwise treating or
adapting any drug with a view to its sale and distribution, but does not include
the compounding or dispensing of any drug or the packing of any drug in the
ordinary course of retail business, and "to manufacture" shall be
construed accordingly; (m)
"manufacturer"
means any person who manufactures a drug; (n)
"net-worth"
means the paid up share capital of a company plus free reserve, if any, and
surpluses excluding outside investment which are not readily available for
operational activity; (o)
"non-Scheduled
bulk drug" means a bulk drug not specified in the First Schedule; (p)
"non-Scheduled
formulation" means a formulation not containing any bulk drug specified in
the First Schedule; (q)
"pre-tax
return" means profits before payment of income-tax and surtax and includes
such other expenses as do not form part of the cost of formulation; (r)
"price
list" means a price list referred to in paragraphs 14 and 15 and includes
a supplementary price list; (s)
"retail
price" means the retail price of a drug arrived at or fixed in accordance
with the provisions of this Order and includes a ceiling price; (t)
"retailer"
means a dealer carrying on the retail business of sale of drugs to customers; (u)
"Scheduled
bulk drug" means a bulk drug specified in the First Schedule; (v)
"Scheduled
formulation" means a formulation containing any bulk drug specified in the
First Schedule either individually or in combination with other drugs,
including one or more than one drug or drugs not specified in the First
Schedule except single ingredient formulation based on bulk drugs specified in
the First Schedule and sold under the generic name; (w)
"sale
turn-over" means the product of units of formulations sold by a
manufacturer or an importer, as the case may be, in an accounting year
multiplied by retail price inclusive of sales tax, if any, paid on direct sales
by the manufacturer or importer but does not include excise duty and local
taxes, if any; (x)
"Schedule"
means a Schedule annexed to this Order; (y)
"wholesaler"
means a dealer or his agent or a stockist appointed by a manufacturer or an
importer for the sale of his drugs to a retailer, hospital, dispensary,
medical, educational or research institution purchasing bulk quantities of
drugs. (1)
The
Government may with a view to regulate the equitable distribution and increasing
supplies of a bulk drug specified in the First Schedule and making it available
at a fair price, from different manufacturers, after making such inquiry as it
deems fit, fix from time to time, by notification in the official Gazette, a
maximum sale price at which such bulk drug shall be sold: Provided that for the purpose of enquiry, in
addition to the information required to be furnished by the manufacturers under
this Order, the manufacturers shall provide any such additional information as
may be required by the Government, and shall allow for inspection of their
manufacturing premises for verification through on the spot study of
manufacturing processes and facilities and records thereof, by the Government. (2)
While
fixing the making sale price of a bulk drug under sub-paragraph (1), the
Government shall take into consideration a post-tax return of fourteen per cent
on net worth or a return of twenty two per cent on capital employed or in
respect of a new plant an internal rate of return twelve per cent based on long
term marginal costing depending upon the option for any of the specified rates
of return that may be exercised by the manufacturer of a bulk drug: Provided that where the production is from
basic stage, the Government shall take into consideration a post-tax return of
eighteen per cent on net worth or a return of twenty six per cent on capital
employed: Provided further that the option with regard
to the rate of return once exercised by a manufacturer shall be final and no
change of rates shall be made without the prior approval of the Government. (3)
No
person shall sell a bulk drug at a price exceeding the maximum sale price fixed
under sub-paragraph (1) plus local taxes, if any: Provided that until the price of a bulk drug
is fixed, by the Government under sub-paragraph (1), the price of such bulk
drug shall be the price which prevailed immediately before the commencement of
this Order and the manufacturer of such bulk drug shall not sell the bulk drug
at a price exceeding the price prevailing immediately before the commencement
of this Order. (4)
Where,
after the commencement of this Order, any manufacturer commences production of
any bulk drug specified in the First Schedule, he shall within fifteen days of
the commencement of production of such bulk drug, furnish the details to the
Government in Form I, and any such additional information as may be required by
the Government and the Government may after receipt of the information and
after making such inquiry as it may deem fit, may fix the maximum sale price of
bulk drug by notification in the Official Gazette. (5)
Any
manufacturer, who desires revision of the maximum sale price of a bulk drug
fixed under sub-paragraph (1) or (4) or as permissible under sub-paragraph (3),
as the case may be, shall make an application to the Government in Form I and
the Government shall after making such enquiry, as it deems fit within a period
of four months from the date of receipt of the complete information, fix a
revised price for such bulk drug or reject the application for revision for
reasons to be recorded in writing. Every manufacturer, producing a Scheduled
bulk drug shall furnish to the Government, (a)
a
list of all Scheduled bulk drugs produced by him within thirty days of the
commencement of this Order and indicate the details of the cost of each of such
bulk drug in Form I; (b)
the
details of the cost of each Scheduled bulk drug produced by him, including such
bulk drug which has been produced after the commencement of this Order, in Form
I by the 30th September, every year. Every manufacturer, producing a non-Scheduled
bulk drug shall furnish to the Government,- (a)
a
list of all such bulk drugs produced by him within thirty days of the
commencement of this Order and indicate the details of the cost of each of such
bulk drugs in Form II; (b)
the
details of the cost of each non-Scheduled bulk drug produced by him, including
such bulk drug which has been produced after the commencement of this Order, in
Form II: Provided that, for the purpose of this
paragraph, the Government may, after making such inquiry as it may deem
necessary in public interest, fix or revise the price of any non-Scheduled bulk
drug and the manufacturer or importer of such bulk drug shall [3][give
effect to the price so fixed or revised, within fifteen days of receipt of the
Order and not sell the such non-Scheduled bulk drug at a price exceeding the
price so fixed or revised thereafter.] (1)
With
a view to achieving adequate production and regulating the equitable
distribution, the Government may, from time to time, by general or special
order, direct any manufacturer of any bulk drug to sell such bulk drug to such
other manufacturers of formulations as may be specified in such order: Provided that while making any such order,
the Government shall have regard to all or any of the following factors,
namely, (i)
the
requirement for captive consumption of such manufacturer, and (ii)
the
requirement of other manufacturers. (2)
For
the purpose of making any order under sub-paragraph (1), the Government may
call for such information from manufacturer, importer or distributor, of bulk
drugs as it may consider necessary and such manufacturer, importer or
distributor shall be bound to furnish such information within such time as may
be specified by the Government. The retail price of a formulation shall be
calculated by the Government in accordance with the following formula, namely: R.P = (M.C. + C.C. + P.M. + P.C.) x
(1+MAPE/100) + E.D. where "R.P." means retail price. "M.C." means materials cost and
includes the cost of drugs and other pharmaceutical aids used including
overages, if any, plus process loss thereon specified as a norm from time to
time by notification in the Official Gazette in this behalf. "C.C." means conversion cost worked
out in accordance with established procedures of costing and shall be fixed as
a norm every year by notification in the Official Gazette in this behalf. "P.M." means Cost of the packing
material used in the packing of concerned formulation, including process loss,
and shall be fixed as a norm every year by notification in the Official Gazette
in this behalf. "P.C." means packing charges worked
out in accordance with established procedures of costing and shall be fixed as
a norm every year by notification in the Official Gazette in this behalf. "MAPE" (Maximum Allowable
Post-Manufacturing Expenses) means all costs incurred by a manufacturer from
the stage of ex-factory cost to retailing and includes trade margin and margin
for the manufacturer and it shall not exceed one hundred per cent for
indigenously manufactured Scheduled formulations; "E.D." means excise duty: Provided that in the case of an imported
formulation, the landed cost shall form the basis for fixing its price along
with such margin to cover selling and distribution expenses including interest
and importer's profit which shall not exceed fifty per cent of the landed cost. Explanation. For the purpose of this proviso,
"landed cost" means the cost of import of formulation inclusive of
customs duty and clearing charges. (1)
The
Government may, from time to time, by order, fix the retail price of a Scheduled
formulation in accordance with the formula laid down in paragraph 7. (2)
Where
the Government fixes or revises the price of any bulk drug under the provisions
of this Order and a manufacturer utilises such bulk drug in his Scheduled
formulations he shall, within thirty days of such fixation or revision, make an
application to the Government, in Form III for price revision of all such
formulations and the Government may, if it considers necessary, fix or revise
the price of such formulation. (3)
The
retail price of a formulation once fixed by the Government under sub-paragraphs
(1) and (2) shall not be increased by any manufacturer except with the prior
approval of the Government. (4)
Any
manufacturer, who desires revision of the retail price of a formulation fixed under
sub-paragraph (1), shall make an application to the Government in Form III or
Form IV, as the case may be, and the Government shall after making such
enquiry, as it deems fit within, a period of two months from the date of
receipt of the complete information, fix a revised price for such formulation
or reject the application for revision for reasons to be recorded in writing. (5)
Notwithstanding
anything contained in the foregoing sub-paragraphs, the retail price of a
Scheduled formulation, of a manufacturer shall, until the retail price thereof
is fixed under the provisions of this Order, be the price which prevailed
immediately before the commencement of this Order, and the manufacturer of such
formulation shall not sell the formulation at a price exceeding the price
prevailing immediately before the commencement of this Order. (6)
No
manufacturer or importer shall market a new pack, if not covered under
sub-paragraph (3) of para 9, or a new formulation or a new dosage form of his
existing Scheduled formulation without obtaining the prior approval of its
price from the Government. (7)
No
person shall sell or dispose of any imported Scheduled formulation without
obtaining the prior approval of its price from the Government. (1)
Notwithstanding
anything contained in this Order, the Government may, from time to time, by
notification in the Official Gazette, fix the ceiling price of a Scheduled
formulation in accordance with the formula laid down in para-graph 7, keeping
in view the cost or efficiency, or both, of major manufacturers of such
formulations and such price shall operate as the ceiling sale price for all
such packs including those sold under generic name and for every manufacturer
of such formulations. (2)
The
Government may, either on its own motion or on application made to it in this
behalf by a manufacturer in Form III or Form IV, as the case may be, after
calling for such information as it may consider necessary, by notification in
the Official Gazette, fix a revised ceiling price for a Scheduled formulation. (3)
With
a view to enabling the manufacturers of similar formulations to sell those
formulations in pack size different to the pack size for which ceiling price
has been notified under the sub-paragraphs (1) and (2), manufacturers shall
work out the price for their respective formulation packs in accordance with
such norms, as may be notified by the Government, from time to time, and he
shall intimate the price of formulation pack, so worked out, to the Government
and such formulation packs shall be released for sale only after the expiry of
sixty days after such intimation: Provided that the Government may, if it
considers necessary, by order revise the price so intimated by the manufacturer
and upon such revision, the manufacturer shall not sell such formulation at a
price exceeding the price so revised. Explanation. For the purpose of this
paragraph the "Scheduled formulation" includes single ingredient
formulation based on bulk drugs specified in the First Schedule and sold under
the generic name. Notwithstanding anything contained in this
Order, (a)
the
Government may, after obtaining such information as may be considered necessary
from a manufacturer or importer, fix or revise the retail price of one or more
formulations marketed by such manufacturer or importer, including a
formulation, in such manner as the pre-tax return on the sales turnover of such
manufacturer or importer does not exceed the maximum pretax return specified in
the Third Schedule; (b)
the
Government may, if it considers necessary so to do in public interest, after
calling for such information by order fix or revise the retail price of any
formulation including a non-Scheduled formulation: (c)
the
Government may, if it considers necessary so to do in public interest, by order
include any bulk drug or formulation in the First Schedule and fix or revise
the prices of such a bulk drug and formulations containing such a bulk drug in
accordance with the provisions of paragraphs 3, 7, 8 and 9 as the case may be. Where any manufacturer, importer of a bulk
drug or formulation fails to submit the application for price fixation or
revision, as the case may be, or to furnish information as required under this
Order, within the time specified therein, the Government may on the basis of
such information as may be available with it, by order fix a price in respect
of such bulk drug or formulation as the case may be. (1)
Notwithstanding
anything contained in this Order, the Government may by notice, require the
manufacturer, importer or distributor, as the case may be, to deposit the
amount which has accrued under the provisions of the Drugs (Prices Control)
Order, 1979 on or before the commencement of this Order, into the Drugs Prices Equalisation
Account and the manufacturer, importer or distributor, as the case may be,
shall deposit the said amount into the said account within such time as the
Government may specify in the said notice. (2)
The
existing amount, if any, in the Drugs Prices Equalisation Account on or before
the date of commencement of this Order, and the amount deposited under
sub-paragraph (1) shall be utilised for, (a)
paying
to the manufacturer, importer or distributor, as the case may be, the shortfall
between his retention price and the common selling price, or as the case may
be, the pooled price for the purpose of increasing the production, or securing
the equitable distribution and availability at fair prices, of drugs; (b)
meeting
the expenses incurred by the Government in discharging the functions under this
paragraph; and (c)
promoting
higher education and research in Pharmaceutical Sciences and Technology and for
the purposes incidental thereto. Notwithstanding anything contained in this
Order, the Government shall by notice, require the manufacturers, importers or
distributors, as the case may be, to deposit the amount accrued due to charging
of prices higher than those fixed or notified by the Government under the
provisions of Drugs (Prices Control) Order, 1987 and under the provisions of
this Order. (1)
Every
manufacturer or importer shall carry into effect the price of a bulk drug or formulation,
as the case may be, as fixed by the Government from time to time, within
fifteen days from the date of notification in the Official Gazette or receipt
of the order of the Government in this behalf by such manufacturer or importer. (2)
Every
manufacturer, importer or distributor of a formulation intended for sale shall
display in indelible print mark on the lable of container of the formulation
and the minimum pack thereof offered for retail sale, the maximum retail price
of that formulation with the words 'retail price not to exceed' preceding it,
and local taxes extra' succeeding it, and words 'inclusive of all taxes'
succeeding it, in the case of non-Scheduled formulations: Provided that in the case of a container
consisting of smaller saleable packs, the retail price of such smaller pack
shall also be displayed on the lable of each smaller pack and such price shall
not be more than the pro rata price of the main pack rounded off the nearest
paisa. (3)
Every
manufacturer or importer shall issue a price list and supplementary price list,
if required, in Form V to the dealers, State Drugs Controllers and the
Government indicating reference to such price fixation or revision as covered
by the order or Gazette notification issued by the Government, from time to
time. (4)
Every
retailer and dealer shall display the price list and the supplementary price
list, if any, as furnished by the manufacturer or importer, on a conspicuous
part of the premises where he carries on business in a manner so as to be
easily accessible to any person wishing to consult the same. (1)
Every
manufacturer, importer or distributor of a non-Scheduled formulation intended
for sale shall display in indelible print mark, on the label of container of
the formulation and the minimum pack thereof offered for retail sale, the
retail price of that formulation with the words [4][retail
price not to exceed] preceding it and the words [5][local
taxes extra] succeeding it: Provided that in the case of a container
consisting of smaller saleable packs, the retail price of such smaller pack
shall also be displayed on the label of each smaller pack and such price shall
not be more than the pro rata retail price of the main pack rounded off to the
nearest paisa. (2)
Every
manufacturer or importer shall issue a price list and supplementary price list,
if required, of the non-Scheduled formulations in Form V to the dealers, State
Drugs Controllers and the Government indicating changes, from time to time. (3)
Every
retailer and dealer shall display the price list and supplementary price list,
if any, as furnished by the manufacturer or importer, on a conspicuous part of
the premises where he carries on business in a manner so as to be easily accessible
to any person wishing to consult the same. No person shall sell any bulk drug or
formulation to any consumer at a price exceeding the price specified in the
current price list or price indicated on the label of the container or pack
thereof, whichever is less, plus all local taxes, if any, payable.][6] No dealer shall sell loose quantity of any
formulation at a price which exceeds the pro rata price of the formulation plus
5 per cent thereof. Subject to the provisions of the Drugs and
Cosmetics Act, 1940 (23 of 1940) and the rules framed thereunder, (a)
no
manufacturer or distributor shall withhold from sale or refuse to sell to a
dealer any drug without good and sufficient reasons; (b)
no
dealer shall withhold from sale or refuse to sell any drug available with him
to a customer intending to purchase such drug. (1)
A
manufacturer, distributor or wholesaler shall sell a formulation to a retailer,
unless otherwise permitted under the provisions of this Order or any order made
thereunder at a price equal to the retail price as specified by an order or
notified by the Government (excluding excise duty, if any), minus sixteen per
cent thereof in the case of price Scheduled drugs. (2)
Notwithstanding
anything contained in sub-paragraph (1), the Government may, by a general or
special order fix, in public interest, the price of formulation sold to the
wholesaler or retailer in respect of any formulation, the price of which has
been fixed or revised under this Order. (1)
Every
manufacturer and importer shall maintain in such form as may be specified by
the Government, records relating to the sales turn-over of individual bulk
drugs manufactured or imported by him, as the case may be, and the sales
turnover of formulations pack-wise and also such other records as may be
directed from time to time by the Government and the Government shall have the
power to call for such records or to inspect such records at the premises of
the manufacturer or importer. (2)
Every
manufacturer or importer shall, within six months of the close of the
accounting year, submit to the Government information in respect of turnover
and allocation of sales and expenses for that year in Form VI. (3)
Every
dealer, manufacturer or importer shall maintain the cash memo or credit memo,
books of account and records of purchase and sale of drugs and shall make
available such records for inspection by the Government or any officer
authorised in this behalf by the Government. (1)
Any
Gazetted Officer of the Central Government or of a State Government authorised
by a general or special order by the Central Government or, as the case may be,
by the State Government in this behalf may, with a view to securing compliance
with this Order or to satisfy himself that the provisions of this Order have
been complied with, (a)
enter
and search any place; (b)
seize
any drug, along with containers, packages, or coverings in which the drug is
found, in respect of which he suspects that any provision of this Order has
been, is being, or is about to be contravened, and thereafter take all measures
necessary for securing production of the drug, containers, packages or
coverings, so seized, in a court of law and for their safe custody pending such
production; (c)
seize
any document, such as, cash memo or credit memo, books, books of account and
records of purchase and sale of the drugs in respect of which he suspects that
any provision of this Order has been, is being, or is about to be contravened. (2)
The
provision of Section 100 of the Code Criminal Procedure, 1973 (2 of 1974),
relating to search and seizure shall, so far as may be, apply to searches and
seizures under this Order. Any person aggrieved by any notification
issued or order made under paragraph 3, 5, 8, 9 or 10 may apply to the
Government for a review of the notification or order within fifteen days of the
date of publication of the notification in the Official Gazette or the receipt
of the order by him, as the case may be, and the Government may make such order
on the application as it may deem proper: Provided that pending a decision by the
Government on the application submitted under the above paragraph, no
manufacturer, importer or distributor as the case may be, shall sell a bulk
drug or formulation as the case may be, at a price exceeding the price fixed by
the Government, of which a review has been applied for. (1)
The
Government, may for the purpose of implementing the provisions of this Order,
authorise any Officer, by a general or special order, to inspect the premises
of any manufacturer, importer, distributor or dealer and such manufacturer,
importer, distributor or dealer shall allow such authorised officer and make
available all relevant informations required for such purpose. (2)
The
Government may, from time to time, issue such guidelines and directions,
consistent with the provisions of this Order, to any manufacturer or importer
as may be necessary, to carry out the provisions of this Order and such
manufacturer or importer shall comply with such guidelines and directions. Any contravention of any of the provisions of
this Order shall be punished in accordance with the provisions of the Essential
Commodities Act, 1955 (10 of 1955). (1)
The
Government may, having regard to the factors mentioned in sub-paragraph (2) and
subject to such conditions, if any, as it may specify, by an order in the Official
Gazette, exempt any manufacturer from the operation of all or any of the
provisions of this Order. (2)
While
granting exemption under sub-paragraph (1), the Government shall have regard to
all or any of the following factors: (a)
number
of workers employed; (b)
amount
of capital invested; (c)
range/group
and type of products manufactured; (d)
sales
turnover; (e)
production
of bulk drugs from basic stage by a process developed through indigenous
research and development, and which is significantly different from known
processes and results in cost reduction; (f)
production
of a new drug which has not been produced elsewhere, if developed through
indigenous research and development. The Government may, by notification in the
Official Gazette, direct that all or any of the powers conferred upon it by
this Order, other than those contained in paragraphs 22, 23 and 25 shall,
subject to such restrictions, exceptions and conditions as may be specified, in
the direction, be exercisable also by such Officer or authority as may be
specified in the notification. (1)
The
Drugs (Prices Control) Order, 1987 is hereby repealed. (2)
Notwithstanding
such repeal, anything done or any action taken, including any notification or
Order made, direction given, notice issued or exemption granted under the Drugs
(Prices Control) Order, 1987, shall, in so far as it is not inconsistent with
the provisions of this Order, be deemed to have been done, taken, made, given,
issued or granted, as the case may be, under the corresponding provisions of
this Order. [See Paragraphs 2 and 3] BULK DRUGS 1.
Sulphamethoxazole 2.
Penicilline 3.
Tetracycline 4.
Rifampicin 5.
Streptomycin 6.
Ranitidine 7.
Vitamin
C 8.
Betamethasone 9.
Metronidazole 10.
Chloroquine 11.
Insulin 12.
Erythromycin 13.
Vitamin
A 14.
Oxytetracycline 15.
Prednisolone 16.
Cephazolin 17.
Methyldopa 18.
Aspirin 19.
Trimethoprim 20.
Cloxacillin 21.
Sulphadimidine 22.
Salbutamol 23.
Famotidine 24.
Ibuprofen 25.
Metamizol
(Analgin) 26.
Doxycycline 27.
Ciprofloxacin 28.
Cefotaxime 29.
Dexamethasone 30.
Ephedrine 31.
Vitamin
B1 (Thiamine) 32.
Carbamazepine 33.
Vitamin
B2 (Riboflavin) 34.
Theophylline 35.
Levodopa 36.
Tolnaftate 37.
Vitamin
E 38.
Nalidixic
Acid 39.
Griseofulvin 40.
Gentamicin 41.
Dextropropoxyphene 42.
Halogenated
Hydroxyquinoline 43.
Pentazocine 44.
Captopril 45.
Naproxen 46.
Pyrental 47.
Sulphadoxine 48.
Norfloxacin 49.
Cefadroxyl 50.
Panthonates
& Panthenols 51.
Furazol
Idone 52.
Pyrithioxine 53.
Sulphadiazine 54.
Framycetin 55.
Verapamil 56.
Amikacin
Sulphate 57.
Glipizide 58.
Spironolactone 59.
Pentoxyfylline 60.
Amodiaquin 61.
Sulphamoxole 62.
Frusemide 63.
Pheniramine
Maleate 64.
Chloroxylenols 65.
Becampicillin 66.
Lincomycin 67.
Chlorpropamide 68.
Mebhydroline 69.
Chlorpromazine 70.
Methendienone 71.
Phenyl
Butazone 72.
Lynestranol 73.
Salazosulphapyrine 74.
Diosmine 75.
Trimipramine 76.
Mefenamic
acid [1]
Vide Notification No. S.O. No. 18 (E). dated January 6, 1995, published in the
Gazette of India (Extra.). Part II. Section 3 (ii), pages 1 to 27, dated 6th
January, 1995. [2]
Inserted by S.O. 733 (E), dated 17th October, 1997, published in the Gazette of
India (Extra.), Part II, Section 3 (ii), pp. 1 and 2, dated 17th October, 1997. [3]
Substituted by Notification No. S.O. 642 (E), dated 19th July, 1995, published
in the Gazette of India (Extra.), Part II, Section 3 (ii), pp. 2-3, dated 19th
July. 1995. [4]
Substituted by Notification No. S.O. 642 (E), dated 19th July, 1995, published
in the Gazette of India (Extra.), Part II, Section 3 (ii), pp. 2-3, dated 19th
July. 1995. [5]
Substituted by Notification No. S.O. 642 (E), dated 19th July, 1995, published
in the Gazette of India (Extra.), Part II, Section 3 (ii), pp. 2-3, dated 19th
July. 1995. [6]
Substituted by Notification No. S.O. 642 (E), dated 19th July, 1995, published
in the Gazette of India (Extra.), Part II, Section 3 (ii), pp. 2-3, dated 19th
July. 1995.THE DRUGS (PRICES CONTROL) ORDER,
1995
PREAMBLE